Figure S3.

CD4⁺ T cell subsets under chronic imatinib treatment. (A) Representative staining for CD45RA and CCR7 to detect naive, central memory, effector memory, and terminally differentiated CD4⁺ T cells in the blood from a healthy donor (HD) and CML patients in CMR or non-CMR. (B and C) Frequencies (B) and the absolute numbers (C) of each subset among CD4⁺ T cells from PBMCs of healthy donors (n = 15) and CML patients in CMR (n = 51) or non-CMR (n = 42). (D and E) IFN-γ and IL-2 production by CD4⁺ T cells stimulated with PMA and ionomycin. Representative staining (D) and percentages (E) of cytokine-producing cells among CD4⁺ T cells from healthy donors (n = 15) and CML patients with CMR (n = 23) or non-CMR (n = 20). (F) Expression of exhausted markers. Frequencies of PD-1–positive or LAG-3–positive CD4⁺ T cells from PBMCs of CML patients in CMR (n = 28) or non-CMR (n = 21). Analyses in E and F were performed in patients from whom sufficient numbers of PBMCs were available. Data are pooled from more than two independent experiments. Horizontal lines in B, C, E, and F indicate medians. Statistical significance was assessed by Mann–Whitney U test. ns, not significant; *, P < 0.05; **, P < 0.01.